Catalyst

Slingshot members are tracking this event:

U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD

100%

Additional Information

Additional Relevant Details Emtricitabine and tenofovir alafenamide are from Gilead Sciences and rilpivirine is from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). Odefsey is Gilead’s second TAF-based regimen to receive FDA approval and represents the smallest pill of any single tablet regimen for the treatment of HIV.
http://www.gilead.co...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 01, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Emtricitabine, Rilpivirine, Tenofovir Alafena, Odefsey, Fda, Approval, Taf-based Regimen, Antiretroviral Treatment, Hiv-1